NASDAQ:LRMR Larimar Therapeutics (LRMR) Stock Price, News & Analysis $9.52 +0.10 (+1.06%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.34▼$9.8850-Day Range$7.02▼$10.6852-Week Range$2.18▼$13.68Volume257,013 shsAverage Volume565,606 shsMarket Capitalization$607.40 millionP/E RatioN/ADividend YieldN/APrice Target$21.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Larimar Therapeutics alerts: Email Address Larimar Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside124.1% Upside$21.33 Price TargetShort InterestBearish5.69% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.29) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.33 out of 5 starsMedical Sector766th out of 936 stocksPharmaceutical Preparations Industry355th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingLarimar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLarimar Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Larimar Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.69% of the outstanding shares of Larimar Therapeutics have been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Larimar Therapeutics has recently increased by 26.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLarimar Therapeutics does not currently pay a dividend.Dividend GrowthLarimar Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LRMR. Previous Next 2.5 News and Social Media Coverage News SentimentLarimar Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Larimar Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for LRMR on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows4 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Larimar Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Larimar Therapeutics is held by insiders.Percentage Held by Institutions91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Larimar Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Larimar Therapeutics are expected to decrease in the coming year, from ($1.29) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Larimar Therapeutics is -9.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Larimar Therapeutics is -9.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLarimar Therapeutics has a P/B Ratio of 5.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Larimar Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Larimar Therapeutics Stock (NASDAQ:LRMR)Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Read More LRMR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LRMR Stock News HeadlinesJuly 24 at 2:11 AM | americanbankingnews.comHead-To-Head Contrast: Larimar Therapeutics (NASDAQ:LRMR) and ProMetic Life Sciences (OTCMKTS:PFSCF)July 16, 2024 | americanbankingnews.comBrokerages Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) Price Target at $21.33July 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 15, 2024 | seekingalpha.comLarimar Therapeutics: More Data Still NeededMay 31, 2024 | seekingalpha.comLarimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely RemovedMay 30, 2024 | globenewswire.comLarimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's AtaxiaMay 29, 2024 | fool.com2 Potentially High-Reward Growth Stocks to Buy Right NowMay 22, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Larimar Therapeutics Post FDA Clinical Hold Lift and Positive Drug Trial TrajectoryJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.May 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Larimar Therapeutics as FDA Lifts Hold on Promising Drug NomlabofuspMay 21, 2024 | msn.comLarimar Therapeutics Advances Friedreich's Ataxia Treatment After FDA Lifts HoldMay 21, 2024 | msn.comLarimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed DrugMay 21, 2024 | markets.businessinsider.comLarimar Therapeutics Says FDA Lifted Partial Clinical Hold For Nomlabofusp In Friedreich's AtaxiaMay 20, 2024 | markets.businessinsider.comOptimistic Outlook for Larimar Therapeutics’ Nomlabofusp Following FDA’s Lifted Partial HoldMay 20, 2024 | finance.yahoo.comLarimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s AtaxiaMay 20, 2024 | globenewswire.comLarimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's AtaxiaMay 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Larimar Therapeutics Backed by Positive Phase 2 Results and Strategic FDA DiscussionsMay 10, 2024 | finance.yahoo.comCompanies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In GrowthSee More Headlines Receive LRMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LRMR CUSIPN/A CIK1374690 Weblarimartx.com Phone(844) 511-9056FaxN/AEmployees42Year FoundedN/APrice Target and Rating Average Stock Price Target$21.33 High Stock Price Target$25.00 Low Stock Price Target$14.00 Potential Upside/Downside+124.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.69% Return on Assets-32.21% Debt Debt-to-Equity RatioN/A Current Ratio17.99 Quick Ratio17.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.86 per share Price / Book5.12Miscellaneous Outstanding Shares63,802,000Free Float61,059,000Market Cap$607.40 million OptionableOptionable Beta1.01 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Carole S. Ben-Maimon M.D. (Age 65)CEO, President & Director Comp: $865kMr. Michael Celano CPA (Age 65)Secretary & CFO Comp: $577.58kDr. Gopi Shankar M.B.A. (Age 53)Ph.D., Chief Development Officer Comp: $593.02kMr. John BermanVice President of Finance & AdministrationMs. Jennifer Spokes JohanssonVice President of Legal & ComplianceDr. Russell G. Clayton Sr. (Age 63)D.O, D.O., Chief Medical Officer Mr. Francis Michael Conway CPAVP & ControllerMore ExecutivesKey CompetitorsFulcrum TherapeuticsNASDAQ:FULCArbutus BiopharmaNASDAQ:ABUSAltimmuneNASDAQ:ALTKamadaNASDAQ:KMDAParatek PharmaceuticalsNASDAQ:PRTKView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 49,102 shares on 7/26/2024Ownership: 0.211%Assenagon Asset Management S.A.Sold 26,156 shares on 7/18/2024Ownership: 0.956%Opaleye Management Inc.Sold 449,087 shares on 5/29/2024Ownership: 0.273%Virtu Financial LLCBought 17,578 shares on 5/20/2024Ownership: 0.028%Ikarian Capital LLCSold 164,340 shares on 5/17/2024Ownership: 0.687%View All Insider TransactionsView All Institutional Transactions LRMR Stock Analysis - Frequently Asked Questions How have LRMR shares performed this year? Larimar Therapeutics' stock was trading at $4.55 on January 1st, 2024. Since then, LRMR stock has increased by 109.2% and is now trading at $9.52. View the best growth stocks for 2024 here. How were Larimar Therapeutics' earnings last quarter? Larimar Therapeutics, Inc. (NASDAQ:LRMR) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.03. Who are Larimar Therapeutics' major shareholders? Top institutional shareholders of Larimar Therapeutics include Assenagon Asset Management S.A. (0.96%) and Bank of New York Mellon Corp (0.21%). Insiders that own company stock include James E Flynn, Michael Celano, Joseph Truitt and Frank E Thomas. View institutional ownership trends. How do I buy shares of Larimar Therapeutics? Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LRMR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
